KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $3.6 billion.

  • Pfizer's Income from Continuing Operations fell 2077.66% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 billion, marking a year-over-year increase of 22299.12%. This contributed to the annual value of $8.1 billion for FY2024, which is 27050.16% up from last year.
  • As of Q3 2025, Pfizer's Income from Continuing Operations stood at $3.6 billion, which was down 2077.66% from $2.9 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Income from Continuing Operations ranged from a high of $9.9 billion in Q3 2022 and a low of -$3.3 billion during Q4 2023
  • Its 5-year average for Income from Continuing Operations is $4.0 billion, with a median of $4.0 billion in 2024.
  • In the last 5 years, Pfizer's Income from Continuing Operations crashed by 12762.29% in 2023 and then surged by 926451.61% in 2025.
  • Pfizer's Income from Continuing Operations (Quarter) stood at $8.2 billion in 2021, then rose by 5.8% to $8.6 billion in 2022, then crashed by 138.57% to -$3.3 billion in 2023, then surged by 234.4% to $4.5 billion in 2024, then dropped by 20.78% to $3.6 billion in 2025.
  • Its Income from Continuing Operations stands at $3.6 billion for Q3 2025, versus $2.9 billion for Q2 2025 and $3.0 billion for Q1 2025.